financetom
Business
financetom
/
Business
/
Bharat Bond ETF: Govt to launch fourth tranche of exchange-traded fund from tomorrow 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bharat Bond ETF: Govt to launch fourth tranche of exchange-traded fund from tomorrow 
Dec 1, 2022 8:32 AM

The government will launch the fourth tranche of Bharat Bond ETF, India’s first corporate bond exchange traded fund, on Friday. The new fund offer of the ETF will open on December 2 and close for subscription on December 8, Edelweiss Mutual Fund, which manages the fund, said in a statement on Thursday.

Share Market Live

NSE

The funds raised would be utilised for undertaking capital expenditures by central public sector enterprises (CPSEs). This new Bharat Bond ETF and Bharat Bond Fund of Fund (FOF) series will mature in April 2033.

Through the launch of this new series in the fourth tranche, the government proposes to raise an initial amount of Rs 1,000 crore with a green shoe option of Rs 4,000 crore.

In December last year, the government had launched the third tranche with a base issue size of Rs 1,000 crore. It was over-subscribed 6.2 times with bids worth Rs 6,200 crore coming in.

The maiden offering of Bharat Bond ETF was launched in 2019, helping CPSEs raise Rs 12,400 crore. In the second and third tranches, it had raised Rs 11,000 crore and Rs 6,200 crore, respectively. The ETF has raised Rs 29,600 crore in its three offerings so far.

Also Read: Fourth tranche of Bharat Bond ETF likely in December

"Bharat Bond ETF programme has received an enthusiastic response from all categories of investors since its launch. Bharat Bond has created a unique opportunity for all Indian investors to invest in PSU Bonds and fuel India’s growth story," Tuhin Kanta Pandey, Secretary, DIPAM, Ministry of Finance, said.

Bharat Bond ETF invests only in 'AAA'-rated bonds of public sector companies.

Since its launch in 2019, the asset under management (AUM) of the ETF has crossed the Rs 50,000 crore-mark.

So far, five maturities of Bharat Bond ETFs have been launched — 2023, 2025, 2030, 2031, and 2032.

"Target Maturity Fund category is growing at an exciting pace post the launch of Edelweiss MF’s Bharat Bond ETF. Investing in long-term debt has been brought to the forefront by these funds. Bharat Bond ETF now has six maturities –- from 2023 to 2033 — which will allow investors to select the right maturity as per their investment goals," Radhika Gupta, MD and CEO, Edelweiss Mutual Fund, said.

Also Read: Govt may raise Rs 100 bn via Bharat Bond ETF by December 2022: Report

(Edited by : Anushka Sharma)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jamf Holding Q3 Non-GAAP Earnings, Revenue Rise
Jamf Holding Q3 Non-GAAP Earnings, Revenue Rise
Nov 10, 2025
05:04 PM EST, 11/10/2025 (MT Newswires) -- Jamf Holding ( JAMF ) reported Q3 Non-GAAP earnings late Monday of $0.25 per diluted share, up from $0.16 a year earlier. Analysts polled by FactSet expected $0.23 per share. Revenue for the quarter ended Sept. 30 was $183.5 million, up from $159.3 million a year earlier. Analysts surveyed by FactSet expected $177.4...
Thermo Fisher Scientific Insider Sold Shares Worth $5,844,850, According to a Recent SEC Filing
Thermo Fisher Scientific Insider Sold Shares Worth $5,844,850, According to a Recent SEC Filing
Nov 10, 2025
05:04 PM EST, 11/10/2025 (MT Newswires) -- Lisa P. Britt, Senior Vice President and Chief Human Resources Officer, on November 07, 2025, sold 10,225 shares in Thermo Fisher Scientific ( TMO ) for $5,844,850. Following the Form 4 filing with the SEC, Britt has control over a total of 14,145 common shares of the company, with 14,145 shares held directly....
Theravance Biopharma Q3 Swings to Adjusted Profit, Revenue Rises
Theravance Biopharma Q3 Swings to Adjusted Profit, Revenue Rises
Nov 10, 2025
05:05 PM EST, 11/10/2025 (MT Newswires) -- Theravance Biopharma ( TBPH ) reported Q3 adjusted earnings late Monday of $0.04 per diluted share, swinging from a loss of $0.06 a year earlier. Three analysts surveyed by FactSet expected a loss of $0.05. Revenue for the three months ended Sept. 30 was $20 million, up from $16.9 million a year earlier....
Kayne Anderson BDC Q3 Net Investment Income Declines; Dividend Maintained
Kayne Anderson BDC Q3 Net Investment Income Declines; Dividend Maintained
Nov 10, 2025
05:03 PM EST, 11/10/2025 (MT Newswires) -- Kayne Anderson BDC ( KBDC ) reported Q3 net investment income late Monday of $0.43 per diluted share, down from $0.52 a year earlier. Analysts polled by FactSet expected $0.40. Total investment income for the quarter ended Sept. 30 was $61.4 million, up from $57.8 million a year earlier. Four analysts surveyed by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved